Loss of ABHD15 Impairs the Anti-lipolytic Action of Insulin by Altering PDE3B Stability and Contributes to Insulin Resistance

Autor:in

Xia, Wenmin; Pessentheiner, Ariane R.; Hofer, Dina C.; Amor, Melina; Schreiber, Renate; Schoiswohl, Gabriele; Eichmann, Thomas O.; Walenta, Evelyn; Itariu, Bianca-Karla; Prager, Gerhard; Hackl, Hubert; Stulnig, Thomas M.; Kratky, Dagmar; Ruelicke, Thomas; Bogner-Strauss, J. G.

Abstrakt

Elevated circulating fatty acids (FAs) contribute to obesity-associated metabolic complications, but the mechanisms by which insulin suppresses lipolysis are poorly understood. We show that alpha/beta-hydrolase domain-containing 15 (ABHD15)is required for the anti-lipolytic action of insulin in white adipose tissue (WAT). Neither insulin nor glucose treatments can suppress FA mobilization in global and conditional Abhd15-knockout (KO) mice. Accordingly, insulin signaling is impaired in Abhd15-KO adipocytes, as indicated by reduced AKT phosphorylation, glucose uptake, and de novo lipogenesis. In vitro data reveal that ABHD15 associates with and stabilizes phosphodiesterase 3B (PDE3B). Accordingly, PDE3B expression is decreased in the WAT of Abhd15-KO mice, mechanistically explaining increased protein kinase A (PKA) activity, hormone-sensitive lipase (HSL) phosphorylation, and undiminished FA release upon insulin signaling. Ultimately, Abhd15-KO mice develop insulin resistance. Notably, ABHD15 expression is decreased in humans with obesity and diabetes compared to humans with obesity and normal glucose tolerance, identifying ABHD15 as a potential therapeutic target to mitigate insulin resistance.

Dokumententyp

Originalarbeit

Open Access Type

Gold

DOI

10.1016/j.celrep.2018.04.055

PubMed ID

MEDLINE:29768196